Abstract
Early VV-ECMO support, combined with prone ventilation and bronchoalveolar lavage, can improve the prognosis of patients with severe pulmonary form of leptospirosis (SPFL). mNGS testing aids in the definitive diagnosis of leptospirosis and provides a reliable basis for antibiotic selection.
Introduction
Leptospirosis is a global zoonotic infection that can rapidly escalate into the Severe Pulmonary Form of Leptospirosis (SPFL). This condition is characterized by Diffuse Alveolar Hemorrhage (DAH) and Acute Respiratory Distress Syndrome (ARDS), carrying a staggering mortality rate of over 52% in intensive care settings. The primary clinical challenge lies in a "vicious cycle": pulmonary hemorrhage renders conventional mechanical ventilation ineffective and potentially harmful due to the high pressures required, while the non-specific early symptoms make rapid diagnosis difficult.
Diagnostic Breakthrough: The Role of mNGS
Traditional diagnostic methods for leptospirosis, such as bacterial culture, are often slow and lack sensitivity. In the reported cases, clinicians utilized Metagenomic Next-Generation Sequencing (mNGS) on blood and bronchoalveolar lavage (BAL) fluid. This molecular approach provided a definitive identification of Leptospira interrogans within 72 hours, enabling a swift transition from broad-spectrum antibiotics to targeted therapies like omadacycline and moxifloxacin.
Multi-Modal Treatment Strategy
The successful management of these patients relied on a combination of advanced life support and specialized maneuvers designed to break the cycle of lung injury:
Early VV-ECMO and "Lung Rest"
Rather than using venovenous extracorporeal membrane oxygenation (VV-ECMO) as a salvage therapy, it was initiated early. This provided "lung rest" by handling gas exchange extracorporeally, allowing clinicians to implement ultra-protective ventilation settings. This strategy prevented the mechanical ventilator from further damaging fragile, bleeding lung tissue.
Navigating the Bleeding Paradox
Standard ECMO protocols require systemic anticoagulation (typically heparin) to prevent circuit thrombosis. However, in the context of massive pulmonary hemorrhage, this poses a significant risk. The authors employed a heparin-free or goal-directed anticoagulation strategy during the initial stages of treatment—extending up to 160 hours in one instance—to stabilize the hemorrhage without compromising the ECMO circuit.
Synergistic Airway Clearance
To address the mechanical obstruction caused by clotted blood, patients underwent prone ventilation and frequent bronchoalveolar lavage (BAL). Prone positioning improved lung recruitment, while BAL physically cleared the airways, facilitating recovery.
Clinical Outcomes
Both patients, aged 69 and 72, achieved full recovery. In Case 2, the oxygenation index (P/F ratio) improved from a critical 66 mmHg to stable levels, allowing for successful decannulation after 255 hours of ECMO support. Both individuals were discharged from the hospital within approximately three weeks of admission.
Conclusion
These cases demonstrate that the high mortality of SPFL can be mitigated through early intervention. The integration of rapid molecular diagnostics (mNGS) with early VV-ECMO support and aggressive airway management represents a viable pathway for treating life-threatening pulmonary leptospirosis. Future efforts should focus on making these resource-intensive technologies more accessible in endemic, resource-limited regions.
Summary updated